Opinion|Videos|July 29, 2024
How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
Advertisement
Video content above is prompted by the following question(s):
- How do you balance the potential clinical benefits of CDK4/6 inhibitors with the cost considerations when making treatment decisions for early breast cancer patients?
Advertisement
Related to this article
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.
Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Secondary T-Cell Cancers After CAR T: Rare, Real, and Worth Watching
5